{"id":67177,"date":"2026-06-03T13:35:59","date_gmt":"2026-06-03T05:35:59","guid":{"rendered":"https:\/\/flcube.com\/?p=67177"},"modified":"2026-06-03T13:36:00","modified_gmt":"2026-06-03T05:36:00","slug":"astrazenecas-next-gen-serd-camizestrant-shows-55-reduction-in-progression-risk-and-superior-ctdna-clearance-in-phase-iii-serena-6-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67177","title":{"rendered":"AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial"},"content":{"rendered":"\n

AstraZeneca plc<\/strong> (NYSE: AZN<\/a>) announced updated results from the Phase III SERENA-6 clinical trial<\/strong>, demonstrating that camizestrant<\/strong>\u2014a next-generation oral selective estrogen receptor degrader (SERD)<\/strong>\u2014in combination with a CDK4\/6 inhibitor<\/strong> maintained significant progression-free survival (PFS) benefits<\/strong> over extended follow-up and achieved statistically significant improvements in second progression-free survival (PFS2)<\/strong>.<\/p>\n\n\n\n

The investigational therapy demonstrated a 55% reduction in disease progression or death risk<\/strong> compared to standard aromatase inhibitor (AI) plus CDK4\/6 inhibitor therapy, while also showing unprecedented circulating tumor DNA (ctDNA) clearance rates<\/strong> that may serve as an early biomarker of treatment efficacy.<\/p>\n\n\n\n

Trial Design & Primary Endpoints<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Trial Name<\/strong><\/td>SERENA-6<\/td><\/tr>
Phase<\/strong><\/td>Phase III<\/td><\/tr>
Design<\/strong><\/td>Randomized, controlled<\/td><\/tr>
Comparator Arm<\/strong><\/td>Aromatase Inhibitor (AI) + CDK4\/6 inhibitor<\/td><\/tr>
Experimental Arm<\/strong><\/td>Camizestrant + CDK4\/6 inhibitor (palbociclib, ribociclib, or abemaciclib)<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Progression-Free Survival (PFS)<\/td><\/tr>
Key Secondary Endpoint<\/strong><\/td>Second Progression-Free Survival (PFS2)<\/td><\/tr>
Exploratory Endpoint<\/strong><\/td>Circulating Tumor DNA (ctDNA) dynamics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Efficacy Results \u2013 PFS and PFS2<\/h2>\n\n\n\n
Endpoint<\/th>Camizestrant Combo<\/th>AI Combo<\/th>Hazard Ratio (95% CI)<\/th>p-value<\/th><\/tr><\/thead>
Median PFS<\/strong><\/td>16.8 months<\/td>9.2 months<\/td>HR: 0.45 (0.34\u20130.59)<\/td><0.00001<\/td><\/tr>
PFS Benefit<\/strong><\/td>+7.6 months extension<\/td>\u2013<\/td>55% risk reduction<\/td>Highly significant<\/td><\/tr>
PFS2<\/strong><\/td>Statistically significant improvement<\/td>\u2013<\/td>\u2013<\/td>Clinically meaningful<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

ctDNA Dynamics \u2013 Week 4\/8 Assessments<\/h2>\n\n\n\n
ctDNA Metric<\/th>Camizestrant Combo<\/th>AI Combo<\/th><\/tr><\/thead>
Median ctDNA Reduction (Week 8)<\/strong><\/td>99% reduction<\/td>64% increase<\/td><\/tr>
Complete ctDNA Clearance Rate<\/strong><\/td>51% of patients<\/td>1.9% of patients<\/td><\/tr>
Statistical Significance<\/strong><\/td>Significantly greater reduction (p<0.0001)<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n